Proteon Therapeutics Appoints Jennifer Panagoulias as Vice President of Regulatory Affairs
01 sept. 2015 07h30 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics Announces Second Quarter 2015 Financial Results
13 août 2015 17h15 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease
13 août 2015 16h45 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics Initiates Second Phase 3 Clinical Study of Investigational Drug Vonapanitase
12 août 2015 07h30 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics Appoints Scott Canute to Its Board of Directors
22 juil. 2015 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., July 22, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics Announces Addition to Russell 2000 Index
29 juin 2015 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., June 29, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics to Present at the JMP Securities Life Science Conference June 24th
17 juin 2015 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., June 17, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Postive Trial Results Of Mesoblast Cell Therapy In Patients With Diabetes And Advanced Chronic Kidney Disease
08 juin 2015 21h12 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, June 8, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results from the Company's Phase 2 trial in patients with diabetic...
Proteon Therapeutics Appoints Scott Toner as Senior Vice President of Marketing
02 juin 2015 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., June 2, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics to Present at Upcoming ERA-EDTA Annual Congress
22 mai 2015 07h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., May 22, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...